Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
58,124.73 +654.91 (+1.14%) CMC Crypto 200
1,260.65 -10.09 (-0.79%)
AnaptysBio, Inc. (ANAB)
After hours:
| Previous close | 24.34 |
| Open | 24.38 |
| Bid | 25.94 x 100 |
| Ask | 26.01 x 100 |
| Day's range | 24.38 - 26.35 |
| 52-week range | 13.36 - 27.50 |
| Volume | |
| Avg. volume | 361,357 |
| Market cap | 710.83M |
| Beta (5Y monthly) | -0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.08 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 45.22 |
ZacksAnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
ZacksWhy You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
